Proof of concept demonstrates PSMA uptake in metastatic pancreatic adenocarcinoma, suggesting new imaging possibilities.
Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography has transformed the imaging of prostate cancer, with an evolving role in nonprostatic malignancies. Metastatic lesions in pancreatic ductal adenocarcinoma have scarcely been reported to show PSMA uptake despite imaging proof of primary tumours showing PSMA uptake. Here, we present the scan evidence of PSMA expression in metastatic sites, providing proof-of-concept for potential imaging and theranostic applications.
No takes yet. Share an insight, caveat, or question.
Priyanka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: